{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T17:49:29Z","timestamp":1777312169806,"version":"3.51.4"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["HL068269"],"award-info":[{"award-number":["HL068269"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["HL068270"],"award-info":[{"award-number":["HL068270"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["HL068279"],"award-info":[{"award-number":["HL068279"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["HL068281"],"award-info":[{"award-number":["HL068281"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["HL068285"],"award-info":[{"award-number":["HL068285"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["HL068288"],"award-info":[{"award-number":["HL068288"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["HL068290"],"award-info":[{"award-number":["HL068290"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["HL068292"],"award-info":[{"award-number":["HL068292"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["HL085057"],"award-info":[{"award-number":["HL085057"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["GM115305"],"award-info":[{"award-number":["GM115305"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010258","name":"Marfan Foundation","doi-asserted-by":"publisher","award":["12N6118N"],"award-info":[{"award-number":["12N6118N"]}],"id":[{"id":"10.13039\/100010258","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","award":["1015006"],"award-info":[{"award-number":["1015006"]}],"id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","award":["ERC-COG-2017-771945"],"award-info":[{"award-number":["ERC-COG-2017-771945"]}],"id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jpeds.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pediatrics"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.jpeds.2020.03.064","type":"journal-article","created":{"date-parts":[[2020,6,22]],"date-time":"2020-06-22T05:20:52Z","timestamp":1592803252000},"page":"213-220.e5","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Variants in ADRB1 and CYP2C9: Association with Response to Atenolol and Losartan in Marfan Syndrome"],"prefix":"10.1016","volume":"222","author":[{"given":"Sara L.","family":"Van Driest","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lynn A.","family":"Sleeper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruce D.","family":"Gelb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaine A.","family":"Morris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harry C.","family":"Dietz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geoffrey A.","family":"Forbus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Goldmuntz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arvind","family":"Hoskoppal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeanne","family":"James","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa M.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jami C.","family":"Levine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer S.","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bart L.","family":"Loeys","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Larry W.","family":"Markham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josephina A.N.","family":"Meester","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seema","family":"Mital","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan D.","family":"Mosley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aaron K.","family":"Olson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marjolijn","family":"Renard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian M.","family":"Shaffer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Sharkey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luciana","family":"Young","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald V.","family":"Lacro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan M.","family":"Roden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpeds.2020.03.064_bib1","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1016\/S0140-6736(05)67789-6","article-title":"Marfan's syndrome","volume":"366","author":"Judge","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.jpeds.2020.03.064_bib2","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/352337a0","article-title":"Marfan syndrome caused by a recurrent de novo missense mutation in the fibrillin gene","volume":"352","author":"Dietz","year":"1991","journal-title":"Nature"},{"key":"10.1016\/j.jpeds.2020.03.064_bib3","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1056\/NEJMoa1404731","article-title":"Atenolol versus losartan in children and young adults with Marfan's syndrome","volume":"371","author":"Lacro","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jpeds.2020.03.064_bib4","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1023\/A:1021477021102","article-title":"Beta-adrenergic receptor polymorphisms: cardiovascular disease associations and pharmacogenetics","volume":"19","author":"Johnson","year":"2002","journal-title":"Pharm Res"},{"key":"10.1016\/j.jpeds.2020.03.064_bib5","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1146\/annurev.pharmtox.43.100901.135823","article-title":"Pharmacology and physiology of\u00a0human adrenergic receptor polymorphisms","volume":"43","author":"Small","year":"2003","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.jpeds.2020.03.064_bib6","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.2217\/pgs-2016-0118","article-title":"Pharmacogenomics of heart failure: a systematic review","volume":"17","author":"Mottet","year":"2016","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.jpeds.2020.03.064_bib7","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/S0009-9236(03)00068-7","article-title":"Beta 1-adrenergic receptor polymorphisms and antihypertensive response to metoprolol","volume":"74","author":"Johnson","year":"2003","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jpeds.2020.03.064_bib8","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.clpt.2006.03.004","article-title":"beta1-Adrenergic receptor polymorphisms influence the response to metoprolol monotherapy in patients with essential hypertension","volume":"80","author":"Liu","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jpeds.2020.03.064_bib9","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.clpt.2004.10.006","article-title":"beta-Adrenergic receptor polymorphisms and responses during titration of metoprolol controlled release\/extended release in heart failure","volume":"77","author":"Terra","year":"2005","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jpeds.2020.03.064_bib10","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1161\/CIRCGENETICS.110.957662","article-title":"Genetic variations in the \u03b1(2A)-adrenoreceptor are associated with blood pressure response to the agonist dexmedetomidine","volume":"4","author":"Kurnik","year":"2011","journal-title":"Circ Cardiovasc Genet"},{"key":"10.1016\/j.jpeds.2020.03.064_bib11","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1097\/FPC.0b013e3280105245","article-title":"Synergistic polymorphisms of beta1 and alpha2C-adrenergic receptors and the influence on left ventricular ejection fraction response to beta-blocker therapy in heart failure","volume":"17","author":"Lobmeyer","year":"2007","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.jpeds.2020.03.064_bib12","doi-asserted-by":"crossref","first-page":"e44324","DOI":"10.1371\/journal.pone.0044324","article-title":"Combinatorial pharmacogenetic interactions of bucindolol and \u03b21, \u03b12C adrenergic receptor polymorphisms","volume":"7","author":"O'Connor","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jpeds.2020.03.064_bib13","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s00392-011-0288-1","article-title":"The Arg389Gly \u03b21-adrenoceptor gene polymorphism influences the acute effects of \u03b2-adrenoceptor blockade on contractility in the human heart","volume":"100","author":"Huntgeburth","year":"2011","journal-title":"Clin Res Cardiol"},{"key":"10.1016\/j.jpeds.2020.03.064_bib14","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/S0009-9236(02)17734-4","article-title":"A common beta1-adrenergic receptor polymorphism (Arg389Gly) affects blood pressure response to beta-blockade","volume":"73","author":"Sofowora","year":"2003","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jpeds.2020.03.064_bib15","doi-asserted-by":"crossref","first-page":"11288","DOI":"10.1073\/pnas.0509937103","article-title":"A polymorphism within a conserved beta(1)-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure","volume":"103","author":"Liggett","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jpeds.2020.03.064_bib16","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1097\/FPC.0b013e3282ef7354","article-title":"Arg389Gly-beta1-adrenergic receptors determine improvement in left ventricular systolic function in nonischemic cardiomyopathy patients with heart failure after chronic treatment with carvedilol","volume":"17","author":"Chen","year":"2007","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.jpeds.2020.03.064_bib17","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1038\/nm930","article-title":"Beta 1-adrenergic receptor polymorphisms confer differential function and predisposition to heart failure","volume":"9","author":"Mialet Perez","year":"2003","journal-title":"Nat Med"},{"key":"10.1016\/j.jpeds.2020.03.064_bib18","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/clpt.2012.18","article-title":"Impact of the \u03b21-adrenoceptor Arg389Gly polymorphism on heart-rate responses to bisoprolol and carvedilol in heart-failure patients","volume":"92","author":"Rau","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jpeds.2020.03.064_bib19","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.jacc.2011.08.061","article-title":"A common \u03b21-adrenergic receptor polymorphism predicts favorable response to rate-control therapy in atrial fibrillation","volume":"59","author":"Parvez","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jpeds.2020.03.064_bib20","doi-asserted-by":"crossref","first-page":"683","DOI":"10.5414\/CP201467","article-title":"Effects of CYP2C9\u22171\/\u22173 and \u22171\/\u221713 on the pharmacokinetics of losartan and its active metabolite E-3174","volume":"50","author":"Bae","year":"2012","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1016\/j.jpeds.2020.03.064_bib21","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s00228-004-0785-5","article-title":"CYP2C9 genetic variants and losartan oxidation in a Turkish population","volume":"60","author":"Babaoglu","year":"2004","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.jpeds.2020.03.064_bib22","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.clpt.2004.04.001","article-title":"Functional impact of CYP2C95, CYP2C96, CYP2C98, and CYP2C911 in\u00a0vivo among black Africans","volume":"76","author":"Allabi","year":"2004","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jpeds.2020.03.064_bib23","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1046\/j.1523-1755.1999.00770.x","article-title":"Angiotensin II type 1 receptor gene polymorphism predicts response to losartan and angiotensin II","volume":"56","author":"Miller","year":"1999","journal-title":"Kidney Int"},{"key":"10.1016\/j.jpeds.2020.03.064_bib24","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1111\/j.1572-0241.2005.41168.x","article-title":"A1166C angiotensin II type 1 receptor gene polymorphism may predict hemodynamic response to losartan in patients with cirrhosis and portal hypertension","volume":"100","author":"Sookoian","year":"2005","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jpeds.2020.03.064_bib25","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1136\/hrt.2004.036897","article-title":"Comparison of the effect of enalapril and losartan in conjunction with surgical coronary revascularisation versus revascularisation alone on systemic endothelial function","volume":"91","author":"Trevelyan","year":"2005","journal-title":"Heart"},{"key":"10.1016\/j.jpeds.2020.03.064_bib26","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s11010-010-0587-2","article-title":"ACE gene polymorphism and serum ACE activity in Iranians type II diabetic patients with macroalbuminuria","volume":"346","author":"Felehgari","year":"2011","journal-title":"Mol Cell Biochem"},{"key":"10.1016\/j.jpeds.2020.03.064_bib27","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.ahj.2007.06.024","article-title":"Rationale and design of a randomized clinical trial of beta-blocker therapy (atenolol) versus angiotensin II receptor blocker therapy (losartan) in individuals with Marfan syndrome","volume":"154","author":"Lacro","year":"2007","journal-title":"Am Heart J"},{"key":"10.1016\/j.jpeds.2020.03.064_bib28","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1002\/(SICI)1096-8628(19960424)62:4<417::AID-AJMG15>3.0.CO;2-R","article-title":"Revised diagnostic criteria for the Marfan syndrome","volume":"62","author":"De Paepe","year":"1996","journal-title":"Am J Med Genet"},{"key":"10.1016\/j.jpeds.2020.03.064_bib29","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.echo.2013.02.018","article-title":"Echocardiographic methods, quality review, and measurement accuracy in a randomized multicenter clinical trial of Marfan syndrome","volume":"26","author":"Selamet Tierney","year":"2013","journal-title":"J Am Soc Echocardiogr"},{"key":"10.1016\/j.jpeds.2020.03.064_bib30","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.amjhyper.2003.09.009","article-title":"Angiotensinogen gene polymorphisms: relationship to blood pressure response to antihypertensive treatment. Results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA) trial","volume":"17","author":"Kurland","year":"2004","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.jpeds.2020.03.064_bib31","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1471-2261-4-16","article-title":"Single nucleotide polymorphisms in the apolipoprotein B and low density lipoprotein receptor genes affect response to antihypertensive treatment","volume":"4","author":"Liljedahl","year":"2004","journal-title":"BMC Cardiovasc Disord"},{"key":"10.1016\/j.jpeds.2020.03.064_bib32","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1097\/HJH.0000000000000714","article-title":"PTPRD gene associated with blood pressure response to atenolol and resistant hypertension","volume":"33","author":"Gong","year":"2015","journal-title":"J Hypertens"},{"key":"10.1016\/j.jpeds.2020.03.064_bib33","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/clpt.2011.185","article-title":"Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing","volume":"90","author":"Johnson","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jpeds.2020.03.064_bib34","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/clpt.2014.159","article-title":"Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and HLA-B genotypes and phenytoin dosing","volume":"96","author":"Caudle","year":"2014","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jpeds.2020.03.064_bib35","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1016\/j.athoracsur.2015.11.024","article-title":"Adjust for multiple comparisons? It's not that simple","volume":"101","author":"Althouse","year":"2016","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.jpeds.2020.03.064_bib36","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1056\/NEJMoa0706585","article-title":"Angiotensin II blockade and aortic root dilation in Marfan\u2019s syndrome","volume":"358","author":"Brooke","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jpeds.2020.03.064_bib37","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1093\/eurheartj\/ehv575","article-title":"Efficacy of losartan vs. atenolol for the prevention of aortic dilation in Marfan syndrome: a randomized clinical trial","volume":"37","author":"Forteza","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jpeds.2020.03.064_bib38","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1016\/j.jacc.2018.07.052","article-title":"Losartan versus atenolol for prevention of aortic dilation in patients with Marfan syndrome","volume":"72","author":"Teixido-Tura","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jpeds.2020.03.064_bib39","doi-asserted-by":"crossref","first-page":"3491","DOI":"10.1093\/eurheartj\/eht334","article-title":"Losartan reduces aortic dilatation rate in adults with Marfan syndrome: a randomized controlled trial","volume":"34","author":"Groenink","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jpeds.2020.03.064_bib40","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.mayocp.2012.11.005","article-title":"Losartan added to \u03b2-blockade therapy for aortic root dilation in Marfan syndrome: a randomized, open-label pilot study","volume":"88","author":"Chiu","year":"2013","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.jpeds.2020.03.064_bib41","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1093\/eurheartj\/ehv151","article-title":"Marfan Sartan: a randomized, double-blind, placebo-controlled trial","volume":"36","author":"Milleron","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jpeds.2020.03.064_bib42","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1080\/00015385.2017.1314134","article-title":"Efficacy of losartan as add-on therapy to prevent aortic growth and ventricular dysfunction in patients with Marfan syndrome: a randomized, double-blind clinical trial","volume":"72","author":"Mui\u00f1o-Mosquera","year":"2017","journal-title":"Acta Cardiol"},{"key":"10.1016\/j.jpeds.2020.03.064_bib43","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.ijcard.2014.11.082","article-title":"A randomized, double blind pilot study to assess the effects of losartan vs. atenolol on the biophysical properties of the aorta in patients with Marfan and Loeys-Dietz syndromes","volume":"179","author":"Sandor","year":"2015","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jpeds.2020.03.064_bib44","doi-asserted-by":"crossref","first-page":"12670","DOI":"10.1074\/jbc.274.18.12670","article-title":"A gain-of-function polymorphism in a G-protein coupling domain of the human beta1-adrenergic receptor","volume":"274","author":"Mason","year":"1999","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jpeds.2020.03.064_bib45","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s10557-010-6220-5","article-title":"Role of beta-adrenergic receptor gene polymorphisms in the long-term effects of beta-blockade with carvedilol in patients with chronic heart failure","volume":"24","author":"Metra","year":"2010","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.jpeds.2020.03.064_bib46","doi-asserted-by":"crossref","first-page":"319","DOI":"10.2217\/pgs.09.158","article-title":"Haplotypes of the adrenergic system predict the blood pressure response to beta-blockers in women with essential hypertension","volume":"11","author":"Filigheddu","year":"2010","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.jpeds.2020.03.064_bib47","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.amjcard.2010.03.041","article-title":"Relation of ADRB1, CYP2D6, and UGT1A1 polymorphisms with dose of, and response to, carvedilol or metoprolol therapy in patients with chronic heart failure","volume":"106","author":"Baudhuin","year":"2010","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jpeds.2020.03.064_bib48","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/S1388-9842(03)00044-8","article-title":"An evaluation of the beta-1 adrenergic receptor Arg389Gly polymorphism in individuals with heart failure: a MERIT-HF sub-study","volume":"5","author":"White","year":"2003","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jpeds.2020.03.064_bib49","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1097\/01213011-200503000-00001","article-title":"Association between beta-1 and beta-2 adrenergic receptor gene polymorphisms and the response to beta-blockade in patients with\u00a0stable congestive heart failure","volume":"15","author":"de Groote","year":"2005","journal-title":"Pharmacogenet Genomics"}],"container-title":["The Journal of Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022347620304431?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022347620304431?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T22:28:48Z","timestamp":1762208928000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022347620304431"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":49,"alternative-id":["S0022347620304431"],"URL":"https:\/\/doi.org\/10.1016\/j.jpeds.2020.03.064","relation":{},"ISSN":["0022-3476"],"issn-type":[{"value":"0022-3476","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Variants in ADRB1 and CYP2C9: Association with Response to Atenolol and Losartan in Marfan Syndrome","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pediatrics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpeds.2020.03.064","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}